The robust quality of the food, pharma, and environmental testing markets is evident from the growth in revenues by 33 percent in 2008 (Media center, 2008). Despite a strong position Eurofins faces certain challenges due to macro drivers like regulations, the global supply chain, and consumer awareness.
Eurofins is planning to close two European facilities and one US site as they want to consolidate and assign assets (GenomeWeb, 2007). It has recently acquired three genomics companies with facilities in Germany and the US and Japan. This has taken place to the competitive market scenario as there is overcapacity in the market and investments are not justified.
Until the mid-1990s, Europe’s biotech industry was closely modeled on the strategies and institutional support structures as in the United States. Any commercialization of biotech research took place directly between academics and the pharmaceutical company. Some firms go in for royalty-bearing licensing like Mycogen to Ciba while others have non-loyalty bearing licensing like AgrEvo and then some even enter into royalties and fees like Monsanto (Renkoski, 1997).
The German biotech industry has suddenly taken off whereas the UK biotech industry has become stagnant. According to Casper and Kettler (2001), there is no one right way to organize commercial biotechnology. Multinational Biotechnology Companies and their Lobby Group.
Ahson, K 1997, What is actually happening in agro-food biotechnology?, Nutrition & Food Science, no. 1, pp. 26–31
Bose, S & Oh, KB 2005, Measuring strategic value-drivers for managing intellectual capital, The Learning Organization, vol. 11, no. 4/5, pp. 347-356
Casper, S & Matraves, C 2003, Institutional frameworks and innovation in the German and UK pharmaceutical industry, Research Policy, vol. 32, pp. 1865–1879
Casper, S & Kettler, H 2001, National Institutional Frameworks and the Hybridization of Entrepreneurial Business Models: The Germany and UK Biotechnological Sectors, Industry and Innovation, vol. 8.
Demirbas, D 2003, The EU Regulation on GMOs, Multinational Biotechnology Companies and their lobby group, Eubios Journal of Asian and International Bioethics, vol. 13, pp. 11-15. retrieved online 22 April 2009, from
D’Souza, C & Quazi, A 2005, The dynamics of exploring future market potential of genetically modified foods, Nutrition & Food Science, vol. 35, no. 2, pp. 95-108
Eurofins, 2009, About Eurofins, retrieved online 22 April 2009, from http://www.eurofins.com/en.aspx
EurActiv, 2005, Biotech industry wants better implementation of EU regulations, retrieved online 22 April 2009, from http://www.euractiv.com/en/health/biotech-industry-wants-better-implementation-eu-regulations/article-144738
Finegold, D & Moser, A 2006, Ethical decision-making in bioscience firms, retrieved online 22 April 2009, from http://www.nature.com/nbt/journal/v24/n3/full/nbt0306-285.html
GenomeWeb, 2007, Eurofins to Close Three Facilities as Operon, MWG, and Medigenomix Subsidiaries Form Genomics Joint Venture, retrieved online 22 April 2009, from
Gurau, C 2004, Positioning strategies in the value-added chain of the biopharmaceutical sector: the case of UK SMEs, Journal of Consumer Marketing, vol. 21, no. 7, pp. 476-485
Knight, JG Mather, DW & Holdsworth, DK 2005, Genetically modified crops and country image of food exporting countries British Food Journal, vol. 107, no. 9, pp. 653-662
Mangematin, V Lemarié, S Boissin, J Catherine, D Corolleur, F Coronini, R & Trommetter, M 2003, Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France, Research Policy, vol. 32, pp. 621–638
Media Centre, 2008, Eurofins continues to experience robust growth; sales increase 33% in Q3 2008, retrieved online 22 April 2009, from http://www.eurofins.com/en/media-centre/press-releases/2008-11-13.aspx
Nilsson, A 2001, Biotechnology Firms in Sweden, Small Business Economics, vol. 17, pp. 93–103
O’Donnell, P 2007, European Biotech Industry Goes on GMO Offensive, retrieved online 22 April 2009, from http://www.soyatech.com/news_story.php?id=5877
Renkoski, MA 1997, Marketing Strategies of Biotechnology Firms: Implications for U.S. Agriculture, Journal of Agricultural and Applied Economics, vol. 29, no. 1, pp. 123–128
Swann, P & Pervezer, M 1996, A comparison of the dynamics of industrial clustering in computing and biotechnology, Research Policy, vol. 25, pp. 1139-I 157
Tucker, G 1996, Biotechnology and enzymes in the food industry, British Food Journal, vol. 98, no. 4/5, pp. 14–19
Please type your essay title, choose your document type, enter your email and we send you essay samples